China’s HEC Plans Novel IPF Study To Make Splash In US
Executive Summary
Tommy Lin, head of Business Development and Global Licensing for HEC Pharma, talks to Scrip’s Brian Yang on how the Chinese domestic drug company is looking to develop its anti-fibrosis drug in the US.